Unique study sequences matched CTC, cfDNA and FFPE sample sets;
Third annual event will be held April 13-16 in Lisbon, Portugal
LOS ANGELES, April 13, 2015 – Cynvenio Biosystems, Inc., the only molecular information technology company that can analyze both cell free DNA (cfDNA) and circulating tumor cells (CTC) from the same blood sample, will present recent findings that establish that both CTC DNA and cfDNA can be used as informative and complementary data types for the analysis of tumor-associated mutations by next generation sequencing (NGS) at the third international Molecular Diagnostics Europe event in Lisbon, Portugal.
The abstract, entitled “LiquidBiopsy: A Molecular Platform to Support Next Generation Sequence Analysis of Circulating Tumor Cells and Circulating Tumor DNA,” will be presented by Cynvenio Chief Scientific Officer Paul Dempsey, Ph.D., as part of the inaugural Circulating Cell-Free Nucleic Acids track on Thursday, April 16 at 3:50 p.m.
This interim dataset was developed as part of an ongoing 60 patient, NCI-funded study to analyze tumor cell populations from blood and tissue (FFPE) in collaboration with researchers at Thomas Jefferson University Cancer Center (Philadelphia), Emory University (Atlanta) and the West Clinic (Memphis, Tennessee).
“The molecular analysis of CTC DNA and cfDNA requires robust enrichment and analytical technology to overcome both limiting template and very high signal to noise ratios. Our methodology derives complementary information from the same blood specimen, and the two templates should be jointly analyzed to fully characterize any given cancer,” notes Dempsey. “We know that cfDNA, or DNA fragments in the bloodstream, are produced in varying levels depending on the size of the tumor. It has also been previously established that CTCs, or whole tumor cells, are related to the aggressiveness of disease in that they have been shown to drive metastatic events.”
During the abstract presentation data will be shared describing how Cynvenio’s LiquidBiopsy platform, a turnkey platform for academic and pharma R&D programs in oncology, supports NGS analysis of CTC and cfDNA from a single blood sample by pairing novel CTC enrichment technologies with high sensitivity sequencing in a single Ion Torrent™ PGM™ run.
In addition to the Circulating Cell-Free Nucleic Acids track, the event will feature three related tracks on the new era in medicine: Prenatal Molecular Diagnostics, Cancer Sequencing and Advanced Diagnostics for Infectious Disease – representing the hottest areas for applying molecular diagnostics to the clinical setting. For more information, visit www.moleculardxeurope.com.
Time and Date: Thursday, April 16, 2015, 3:50 p.m.
Title: LiquidBiopsy: A Molecular Platform to Support Next Generation Sequence Analysis of Circulating Tumor Cells and Circulating Tumor DNA
Track: Circulating Cell-Free Nucleic Acids
Type: Session, sponsored by Thermo Fisher Scientific
Location: Marriott Hotel, Lisbon, Portugal
Presenter: Paul W. Dempsey, Cynvenio Biosystems Inc.
Ian Torrent and PGM are trademarks of Thermo Fisher Scientific.
About Cynvenio Biosystems, Inc.
Cynvenio is a molecular information technology company that helps make individualized cancer treatment possible by providing longitudinal insights into each patient via the genomic analysis of their cancer from a standard blood draw.
Cynvenio’s LiquidBiopsy® clinical assays for solid tumors are used as therapy finders to periodically assess patients’ individual mutations and match them with targeted cancer therapies and clinical trials. The company’s tests complement traditional tissue biopsy analysis or can be used as standalone tests to identify therapies for patients in which tissue biopsy is deemed difficult or too risky to collect.
Cynvenio is headquartered in Westlake Village, California (Los Angeles). For more information, visit http://www.cynvenio.com.
LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.